The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report on Recurrent Salivary Duct Carcinoma Treated with Casodex/Nolvadex and Traditional Korean Medicine

Casodex/Nolvadex와 한방치료를 병행하여 호전된 재발성 침샘관암 환자 1례

  • Received : 2021.09.17
  • Accepted : 2021.10.22
  • Published : 2021.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This study examined the case of a patient with recurrent salivary duct carcinoma and hepatic metastasis. Methods: The patient was treated with Casodex/Nolvadex from January 25th 2021 onward with doses of bicalutamide (150 mg/day) and tamoxifen (10 mg/day) every four weeks. Simultaneously, the patient was treated with Korean medicine. The tumor size was measured using computed tomography (CT). Adverse events were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Results: Following the four-month treatment, the extent of the proximal portion of hepatic metastasis decreased, and discomfort and physical activity gradually improved. Conclusions: The results suggest that combined chemotherapy and Korean medicine may help to reduce tumor size and improve quality of life.

Keywords

References

  1. Ellis GL, Auclair RL. Tumors of the Salivary Glands. Washington, DC. Armed forces institute of pathology; 2008. Atlast of Tumor Pathology; 4th series.
  2. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med 2009;133(11):1763-74. https://doi.org/10.5858/133.11.1763
  3. Annual report of cancer statistics in korea in 2018. National Cancer Center. Published 2021. Accessed January, 2021.
  4. Sung IY, Kim UK, Kim JR, Chung IK. A Clincial Study on Malignant Salivary Gland Tumors. Journal of the Korean Association of Oral and Maxillofacial Surgeons 2000;26(4):427-34.
  5. Lee JH, Shin DH. Pathological Classification and Diagnosis of the Salivary Gland Tumors. J Clin Otolaryngol Head Neck Surg 2020;31(1):18-28. https://doi.org/10.35420/jcohns.2020.31.1.18
  6. Park SU, Kang SY, Kim TH, Kim CH. A Case Report of Salivary Duct Carcinoma. J Korean Soc Plast Reconstr Surg 2008;35(5):607-10.
  7. 박종완, 최문영. Trastuzumab으로 치료한 HER2 양성 타액관암 1례. 2018년 제69차 대한내과학회 추계학술대회 2018:504.
  8. Murase R, Sumida T, Ishikawa A, Murase R, McAllister SD, Hamakawa H, et al. Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer. Int J Otolaryngol 2011;2011:187623. doi: 10.1155/2011/187623.
  9. Lee YJ, Koh YW, Yoon SO, Ryu HJ, Kim HR, Shin HA. Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker. Korean Journal of Head & Neck Oncology 2019;35(1):13-20. https://doi.org/10.21593/kjhno/2019.35.1.13.
  10. Sohaib A. RECIST rules. Cancer Imaging 2012;12(2):345-6. https://doi.org/10.1102/1470-7330.2012.9011
  11. Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, et al. [New Response Evaluation Criteria in Solid Tumours-Revised RECIST Guideline(version 1.1).]. Cancer & chemotherapy 2009;36(13):2495-501.
  12. Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. Availablefrom:URL:https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Published 2020. Accessed August 14, 2020.
  13. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Metastatic. 2021.
  14. Kim GH, Sung MW, Kim DY, Jung HS. Salivary Duct Carcinoma-2 Case Reports. Korean J Otolaryngol 2000;43:1129-33.
  15. Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma. Samsung Medical Center. URL: https://clinicaltrials.gov/ct2/show/NCT03614364
  16. Park MH, Ryu HS, Ro HY. Cho JS, Yoon JH, Jegal Yj, et al. The Clinical Significance of the Estrogen Receptor βExpression for Endocrine Therapy in Patients with ERα-negative and Progesterone Receptor-positive Breast Carcinoma. Breast Cancer 2009 Sep;12(3):156-62. https://doi.org/10.4048/jbc.2009.12.3.156
  17. Di Villeneuve L, Souza IL, Tolentino FDS, Ferrarotto R, Schvartsman G. Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front Oncol 2020 Oct 22;10:580141. https://doi.org/10.3389/fonc.2020.580141
  18. Yoo HS, Lee YY, Song KC, Choi BL, Seo SH, Cho JH, et al. The Effects of HangAmDan (HAD) on Anti-Metastasis and Preventing Relapses, Administered to 69 Cancer Patients. The Journal of Internal Korean Medicine 2002;23(2):165-73.
  19. Han SS, Cho CK, Lee YW, Yoo HS. A Case Report on Extranodal Marginal Zone B Cell of Mucosa-associated Lymphoid Tissue (MALT) Type Lymphoma Treated with Hangam-dan. The Journal of Internal Korean Medicine 2008;29(3):810-8.
  20. 이인선, 장인규. An Experimental Study on Some Effects of SOEUMIN-HYANGSAYANGYUI-TANG. 경희한의대논문집 1989;12(1):153-70.
  21. Kim JH, Shin HK. Analysis of Biological Experiment on Immunoactivity of Sipjeondabo-tang. Korean J Oriental Physiology & Pathology 2012;26(5):641-9.
  22. Yoon JH, Choi SH, Ahn KS. Anti-metastatic Effects of Shiquandabutang on Human Fibrosarcoma cells HT1080. J of Kor Oriental Oncology 1998;4(1):131-46.
  23. The Society of Internal Korean Medicine. Korean Medicine Clinical Practice Guideline for Functional Dyspepsia 2020.
  24. Yook TH, Song BY, Kim JW, Choi YM, Nam SS, Park YC, et al. Korean Medicine Clinical Practice Guideline for Facial Palsy 2019.
  25. Toriyama-Baba H, Ligo M, Asamoto M, Iwahori Y, Park CB, Han BS, et al. Organotropic Chemopreventive Effects of n- 3 Unsaturated Fatty Acids in a Rat Multi-organ Carcinogenesis Model. Jpn J Cancer Res 2001;92(11):1175-83. https://doi.org/10.1111/j.1349-7006.2001.tb02137.x
  26. 건강보험심사평가원. 요법코드 2149.